More than 1,500 people who have sought support from the vaccine damage payment scheme after being injured or bereaved as a ...
Moderna (MRNA) stock gained in the premarket after the company received a tender to supply its COVID-19 vaccine in the EU, ...
Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.
The biotech, renowned for its pioneering development of vaccines ... could be the booster shot the stock needs to generate a rebound. It's been more than four years since Moderna rose to ...
The U.S. government has handed Moderna almost $600 million to accelerate its work on various bird flu vaccines as well as work on mRNA vaccines for other influenza strains with pandemic potential.
Under the resulting agreement, 17 participating countries can access Moderna's mRNA COVID-19 vaccine for up to four years. "This agreement presents an opportunity for Moderna to support and ...
Moderna stock has been under pressure amid declining sales of its COVID-19 vaccine. The company projects ... in clinical trials that could be the booster shot the stock needs to generate a rebound.